VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2022 | Validation of POLAR, a 16-gene molecular signature, for breast conserving surgery +/- radiotherapy

Per Karlsson, MD, Gothenburg Universit, Gothenburg, Sweden, provides an overview of the Profile for the Omission of Local Adjuvant Radiotherapy (POLAR), a 16-gene molecular signature developed to identify which patients with invasive breast cancer need radiation after breast conserving surgery. The 16 genes included in POLAR are involved in immune response and proliferation. The POLAR signature was developed from a randomized Swedish Breast Cancer Group 91 Radiotherapy trial (SweBCG91RT), where patients were randomized to radiotherapy or not after breast conservative surgery. Tumor samples were collected from all patients in this study and gene expression analysis was carried out. The signature was then validated via a meta-analysis of three randomized trials of breast conserving surgery with or without radiotherapy, including SweBCG91RT, Scottish Conservation Trial (SCT) and Princess Margaret Hospital (PMH). The meta-analysis indicated the POLAR signature can effectively identify patients who will benefit from postoperative radiotherapy and is prognostic for locoregional recurrence. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter